Myeloma UK will attend the European Haematology Association (EHA) Congress between 22 and 25 June in Madrid.
This is the second high-profile clinical conference Myeloma UK is taking part in this month, following our visit to the Health Technology Assessment International (HTAi) annual conference in Rome.
The EHA is a not-for-profit membership organisation that promotes excellence in patient care, research and education in haematology.
Its annual Congress provides a platform for experts from across the globe to present original data, as well as sharing evidence-based knowledge, such as clinical trial data.
It also lets haematologists and researchers access the latest clinical research in haematology, discover new techniques and approaches to treatment, and share new research and ideas.
On Friday, 23 June, Myeloma UK Health Services Research Manager, Dr Jayne Galinsky, will share findings at EHA from a patient preference survey conducted by Myeloma UK in collaboration with Dr Simon Fifer from Community and Patient Preference Research (CaPPRe).
The survey sought to discover exactly what myeloma patients want from treatments.
Jayne said, “Myeloma UK is a patient-centred organisation, so having the opportunity to present findings that accurately reflect patient preferences on this global stage is extremely important to us.
“We hope that our findings will help researchers decide what treatments to develop for myeloma patients and support our work to help deliver better treatments now and in the future.”
She added, “Attending the EHA Congress is also a great opportunity to meet with our partners and network with industry experts from across the globe, which can help us develop future project ideas and collaborations.”